Comparative Analysis of Safety Data of Four Treatment Regimens in Early Rheumatoid Arthritis Patients

    June 2013 in “ Annals of the Rheumatic Diseases ”
    Е М Федоренко, G. Lukina, Ya. A. Sigidin, Д. Е. Каратеев, E. Luchikhina, E. Nasonov
    TLDR Methotrexate plus prednisolone had the fewest serious side effects.
    The study compared the safety of four different DMARD treatment regimens in 141 early rheumatoid arthritis patients over one year. The regimens included methotrexate (MTX), MTX plus prednisolone (MTX-P), MTX-P plus methylprednisolone (MTX-P-MP), and leflunomide (LEF). Side effects were similar across groups, with 9 patients in each group experiencing them. Serious side effects leading to treatment discontinuation were most common in the LEF group, while no patients in the MTX-P group had to stop treatment. Overall, side effects were generally moderate or minimal.
    Discuss this study in the Community →